Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole Prophylaxis in High-Risk Hematology Patients
NCT02875743Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Dec 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of posaconazole in invasive fungal disease (IFD), sponsored by King's College Hospital. Primary endpoint: Cumulative incidence of Invasive Fungal Disease at 24 weeks. Started Dec 2016; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive fungal disease (IFD)
Beyond the preview
Go deeper on NCT02875743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875743.